We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

59 hedge funds and large institutions have $139M invested in VYNE Therapeutics in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $68.4M → $139M (+$70.6M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

60% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 15

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

5% more funds holding

Funds holding: 56 → 59 (+3)

0.06% more ownership

Funds ownership: 0.99% → 1.06% (+0.06%)

Holders
59
Holders Change
+3
Holders Change %
+5.36%
% of All Funds
1.28%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
10
Increased
24
Reduced
15
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
+$6.21M
2
O
OrbiMed
New York
+$4.23M
3
MP
Mangrove Partners
Connecticut
+$3.74M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.52M
5
DM
Deerfield Management
New York
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$5.23M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.07M
3
GPP
Great Point Partners
Connecticut
-$982K
4
AIM
Alambic Investment Management
California
-$703K
5
JP Morgan Chase
JP Morgan Chase
New York
-$564K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$19K -$1.44K -3 -8%
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
$16.5K +$11.5K +24 +480%
UBS Group
53
UBS Group
Switzerland
$15K -$44.6K -93 -78%
Legal & General Group
54
Legal & General Group
United Kingdom
$9K – – –
MAM
55
Meeder Asset Management
Ohio
$7K -$1.44K -3 -19%
Federated Hermes
56
Federated Hermes
Pennsylvania
$4K -$480 -1 -11%
AIP
57
Ameritas Investment Partners
Nebraska
$4K – – –
PNC Financial Services Group
58
PNC Financial Services Group
Pennsylvania
$2K – – –
PCP
59
Proficio Capital Partners
Massachusetts
$1K +$480 +1 New
NHAS
60
Novo Holdings A/S
Denmark
– -$5.23M -17,627 Closed
MWNA
61
Marshall Wace North America
New York
– -$80K -269 Closed
Citadel Advisors
62
Citadel Advisors
Florida
– -$57K -193 Closed
Macquarie Group
63
Macquarie Group
Australia
– -$5K -18 Closed
Fidelity Investments
64
Fidelity Investments
Massachusetts
– -$1K -5 Closed
Royal Bank of Canada
65
Royal Bank of Canada
Ontario, Canada
– -$1K -3 Closed
Bank of Montreal
66
Bank of Montreal
Ontario, Canada
– -$1K -2 Closed
1 2
3

VYNE Hedge Fund Activity: Q1 2019 in Review

59 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2019, worth a combined $139M — up 103% from $68.4M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new VYNE positions and 7 closed out — a net gain of 3 holders — while 24 added to existing stakes and 15 trimmed.

The largest buyer was First Manhattan, adding an estimated $6.21M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $5.23M sold.

  • 59 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2019, up from 56 in Q4 2018.
  • Funds reported $139M of VYNE Therapeutics stock for Q1 2019, up 103% quarter-over-quarter.
  • 10 funds opened new VYNE Therapeutics positions in Q1 2019 and 7 closed out, a net change of +3 holders.
  • The largest VYNE Therapeutics buyer in Q1 2019 was First Manhattan, an estimated $6.21M added.
  • The largest VYNE Therapeutics seller in Q1 2019 was Novo Holdings A/S, an estimated $5.23M sold.

Based on aggregated 13F filings for Q1 2019.